InvestWiser

Boule Diagnostics AB

BOULNasdaq StockholmHealthcareMarket value 47 m SEK
1.21SEK −5.5%
last day · Price as of 18 November 2026

The answer first

Does Boule Diagnostics beat the market?

No, Boule Diagnostics has not beaten the market over the last year.

Boule Diagnostics−78.0%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 5% of Nordic stocks

    • Quality8
    • Value53
    • Trend2

    No. 178 of 195 in healthcare

  • Expectations in the price

    Low expectations

    For the share to return about 9% a year from today's price, it is enough that the cash Boule Diagnostics keeps shrinks about 28% a year for 10 years.

Max for seven days

Follow Boule Diagnostics with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Boule Diagnostics

From today, at a price of 1.21 SEK. Write why you follow Boule Diagnostics, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Boule Diagnostics

Your first answer is free, no account needed.

Do you own Boule Diagnostics, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Boule Diagnostics and a few more. Free, no card.

Past year against the exchange and Super Stock
Boule Diagnostics−78.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Boule Diagnostics has fallen 78.0% over the past year, including dividends.
  • Overall, Boule Diagnostics ranks better than 5% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 93.2%. The price is 98.4% below its peak now.

Who owns Boule Diagnostics? See the major shareholders and their stakes

What do analysts think of Boule Diagnostics?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

5

Quality, value and trend together. Better than 5% of Nordic stocks.

No. 178 of 195 in healthcare

Quality8
The company · Fundamentals: the accounts

Low Weaker accounts than most: low profitability, high debt or uneven results.

No. 187 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity1.73
  • Asset turnoverSales divided by everything the company owns0.93
  • Return on equityProfit divided by equity−10.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value53
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 46 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.3
  • P/SPrice divided by sales0.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flow1.7

The ranking is built on P/E, P/B and P/S.

Trend2
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 187 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−62.9%
  • 6 months−65.8%
  • 9 months−70.6%
  • 12 months−78.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−40.3%
3 years, per year
−49.6%
5 years, per year
−50.2%
10 years, per year
−29.1%
Largest fall, 3 years
−93.2%
From a peak to the bottom
From the peak now
−98.4%
How far the price is from the peak
Volatility, 1 year
81.9%
How much the price swings over a year
Beta, 1 year
0.40
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Boule Diagnostics

3 funds we follow own Boule Diagnostics. The share is how much of the fund the stock makes up.

  • Sweden3

From the funds' latest known holdings.

About Boule Diagnostics

Boule Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 200 employees.

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms.

See the full analysis of Boule Diagnostics.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market